BrightGene Health

Development History
 
 
2001
BrightGene was formally established.
 
2006
Develop an entecavir synthesis process with independent rights
 
2010
Completed Series A financing and Lilly Asia Ventures became a shareholder.
Established a wholly-owned subsidiary, Xintai Pharmaceuticals.
Acquired Jiangsu Senran Chemical.
Acquired Chongqing Qiantai Biology.
 
2012
Completed Series B financing of 60 million yuan, led by Lilly;
The wholly-owned subsidiary Xintai Pharmaceutical was built
 
2015
Completed Series C financing of 150 million yuan, with CICC inves... [Details]